You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlunisolide
Accession NumberDB00180  (APRD00976)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionFlunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis. The principle mechanism of action of flunisolide is to activate glucocorticoid receptors. It also has anti-inflammatory action.
Structure
Thumb
Synonyms
Flunisolida
Flunisolide
Flunisolide anhydrous
Flunisolidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aerospanaerosol, metered80 ug/1respiratory (inhalation)MEDA Pharmaceuticals2012-03-01Not applicableUs
Aerospanaerosol, metered80 ug/1respiratory (inhalation)Acton Pharmaceuticals, Inc.2012-03-01Not applicableUs
Bronalide Inhal 250mcg/aemmetered-dose aerosol250 mcginhalationBoehringer Ingelheim (Canada) Ltd Ltee1988-12-311999-02-15Canada
Novo-flunisolidespray25 mcgnasalNovopharm Limited1998-06-302005-08-10Canada
PMS-flunisolidespray0.025 %nasalPharmascience Inc1994-12-312009-08-27Canada
Ratio-flunisolidespray25 mcgnasalRatiopharm Inc Division Of Teva Canada Limited1993-12-312010-08-02Canada
Rhinalarspray.025 %nasalSyntex Inc.1978-12-311996-09-30Canada
Rhinalar Nasal Mistsolution; spray25 mcgnasalIvax Laboratories Incorporated1996-12-312015-10-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-flunisolide Nasal Spraymetered-dose pump0.25 mgnasalApotex Inc2000-03-10Not applicableCanada
Flunisolidesolution.25 mg/mLnasalBausch & Lomb Incorporated2002-02-20Not applicableUs
Flunisolidesolution.25 mg/mLnasalREMEDYREPACK INC.2016-02-17Not applicableUs
Flunisolidesolution.25 mg/mLnasalPhysicians Total Care, Inc.2003-05-23Not applicableUs
Flunisolidespray, metered.25 mg/mLnasalRising Pharmaceuticals, Inc2006-08-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AeroBidRoche
BronalideKrewel
NasalideTeva Santé
NasarelNot Available
SyntarisTeva
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flunisolide acetate
4533-89-5
Thumb
  • InChI Key: WEGNFRKBIKYVLC-XTLNBZDDSA-N
  • Monoisotopic Mass: 476.221031566
  • Average Mass: 476.541
DBSALT001846
Flunisolide hemihydrate
77326-96-6
Thumb
  • InChI Key: MIXMJCQRHVAJIO-TZHJZOAOSA-N
  • Monoisotopic Mass: 886.431498447
  • Average Mass: 887.024
DBSALT001845
Categories
UNII78M02AA8KF
CAS number3385-03-3
WeightAverage: 434.4977
Monoisotopic: 434.210466929
Chemical FormulaC24H31FO6
InChI KeyInChIKey=XSFJVAJPIHIPKU-XWCQMRHXSA-N
InChI
InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[[email protected]](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the maintenance treatment of asthma as a prophylactic therapy.
PharmacodynamicsFlunisolide is a synthetic corticosteroid. It is administered either as an oral metered-dose inhaler for the treatment of asthma or as a nasal spray for treating allergic rhinitis. Corticosteroids are naturally occurring hormones that prevent or suppress inflammation and immune responses. When given as an intranasal spray, flunisolide reduces watery nasal discharge (rhinorrhea), nasal congestion, postnasal drip, sneezing, and itching oat the back of the throat that are common allergic symptoms.
Mechanism of actionFlunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
Related Articles
AbsorptionAbsorbed rapidly
Volume of distributionNot Available
Protein bindingApproximately 40% after oral inhalation
Metabolism

Primarily hepatic, converted to the S beta-OH metabolite.

Route of eliminationNot Available
Half life1.8 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.9683
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7912
P-glycoprotein inhibitor INon-inhibitor0.5674
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8304
CYP450 2C9 substrateNon-substrate0.8679
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.6964
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9311
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8806
Ames testNon AMES toxic0.7682
CarcinogenicityNon-carcinogens0.9174
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7033 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.671
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roche palo alto llc
  • Acton pharmaceuticals inc
  • Apotex inc richmond hill
  • Bausch and lomb pharmaceuticals inc
  • Qpharma llc
  • Ivax research inc
  • Teva branded pharmaceutical products r and d inc
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredrespiratory (inhalation)80 ug/1
Metered-dose pumpnasal0.25 mg
Metered-dose aerosolinhalation250 mcg
Solutionnasal.25 mg/mL
Spray, meterednasal.25 mg/mL
Spraynasal0.025 %
Spraynasal25 mcg
Spraynasal.025 %
Solution; spraynasal25 mcg
Prices
Unit descriptionCostUnit
Aerobid 250 mcg/act Aerosol 7 gm Inhaler101.95USD inhaler
Aerobid-M 250 mcg/act Aerosol 7 gm Inhaler101.95USD inhaler
Flunisolide 29 mcg/act Solution 25ml Bottle57.16USD bottle
Flunisolide 0.025% Solution 25ml Bottle48.35USD bottle
Aerobid aerosol with adapter14.0USD g
Aerobid-m aerosol with adapter14.0USD g
Flunisolide 29 mcg-0.025% spray2.2USD ml
Nasarel 29 mcg-0.025% spray1.98USD ml
Apo-Flunisolide 0.025 % Spray0.62USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5776433 No1995-07-072015-07-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226-230American Cyanamid Co.; British Patent 933,867; August 14, 1963.
water solubilityPractically insolubleNot Available
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0374 mg/mLALOGPS
logP2.2ALOGPS
logP1.56ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.73ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity111.89 m3·mol-1ChemAxon
Polarizability44.88 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Richard E. Jones, Jacquelyn A. Smithers, “Process for preparing flunisolide.” U.S. Patent US4273710, issued July, 1965.

US4273710
General ReferencesNot Available
External Links
ATC CodesR01AD04R03BA03
AHFS Codes
  • 52:08.08
PDB EntriesNot Available
FDA labelDownload (4.31 MB)
MSDSDownload (74.3 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Flunisolide is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flunisolide.
AldesleukinFlunisolide may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Flunisolide can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Flunisolide can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flunisolide.
AmiodaroneThe serum concentration of Flunisolide can be increased when it is combined with Amiodarone.
Amphotericin BFlunisolide may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Flunisolide can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Flunisolide can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Flunisolide can be decreased when combined with Atomoxetine.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Flunisolide.
BazedoxifeneThe serum concentration of Flunisolide can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFlunisolide may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Flunisolide.
BexaroteneThe serum concentration of Flunisolide can be decreased when it is combined with Bexarotene.
Bismuth SubcitrateThe bioavailability of Flunisolide can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Flunisolide can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Flunisolide can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Flunisolide can be decreased when it is combined with Bosentan.
BumetanideFlunisolide may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flunisolide.
Calcium carbonateThe bioavailability of Flunisolide can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Flunisolide can be decreased when it is combined with Carbamazepine.
CeritinibThe serum concentration of Flunisolide can be increased when it is combined with Ceritinib.
CeritinibFlunisolide may increase the hyperglycemic activities of Ceritinib.
ChlorothiazideFlunisolide may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Flunisolide can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneFlunisolide may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Flunisolide can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Flunisolide can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Flunisolide can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Flunisolide can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Flunisolide can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Flunisolide can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flunisolide.
CoumaphosThe risk or severity of adverse effects can be increased when Flunisolide is combined with Coumaphos.
CrizotinibThe metabolism of Flunisolide can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Flunisolide can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Flunisolide can be decreased when it is combined with Dabrafenib.
DarunavirThe serum concentration of Flunisolide can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Flunisolide can be increased when it is combined with Dasatinib.
DecamethoniumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Decamethonium.
DeferasiroxThe serum concentration of Flunisolide can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Flunisolide is combined with Deferasirox.
DelavirdineThe metabolism of Flunisolide can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Demecarium.
DexamethasoneThe serum concentration of Flunisolide can be decreased when it is combined with Dexamethasone.
DichlorvosThe risk or severity of adverse effects can be increased when Flunisolide is combined with Dichlorvos.
DienestrolThe serum concentration of Flunisolide can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Flunisolide can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunisolide.
DihydroergotamineThe metabolism of Flunisolide can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneFlunisolide may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Flunisolide can be decreased when combined with Diltiazem.
DonepezilThe risk or severity of adverse effects can be increased when Flunisolide is combined with Donepezil.
DoxycyclineThe metabolism of Flunisolide can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Flunisolide can be decreased when combined with Dronedarone.
EchothiophateThe risk or severity of adverse effects can be increased when Flunisolide is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Edrophonium.
EfavirenzThe serum concentration of Flunisolide can be decreased when it is combined with Efavirenz.
EnzalutamideThe serum concentration of Flunisolide can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Flunisolide can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Flunisolide can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Flunisolide can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Flunisolide can be increased when it is combined with Estriol.
EstroneThe serum concentration of Flunisolide can be increased when it is combined with Estrone.
Etacrynic acidFlunisolide may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Flunisolide can be increased when it is combined with Ethinyl Estradiol.
EtravirineThe serum concentration of Flunisolide can be decreased when it is combined with Etravirine.
FenthionThe risk or severity of adverse effects can be increased when Flunisolide is combined with Fenthion.
FluconazoleThe metabolism of Flunisolide can be decreased when combined with Fluconazole.
FluoxymesteroneFlunisolide may increase the fluid retaining activities of Fluoxymesterone.
FluvoxamineThe metabolism of Flunisolide can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Flunisolide can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Flunisolide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Flunisolide can be decreased when it is combined with Fosphenytoin.
FurosemideFlunisolide may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Flunisolide can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Flunisolide can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Flunisolide.
HexestrolThe serum concentration of Flunisolide can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Flunisolide is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunisolide.
HydrochlorothiazideFlunisolide may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideFlunisolide may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Flunisolide can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Flunisolide can be decreased when combined with Imatinib.
IndacaterolIndacaterol may increase the hypokalemic activities of Flunisolide.
IndapamideFlunisolide may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Flunisolide can be increased when it is combined with Indinavir.
IsavuconazoniumThe metabolism of Flunisolide can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Flunisolide is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Flunisolide.
IsradipineThe metabolism of Flunisolide can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Flunisolide can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Flunisolide can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Flunisolide can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Flunisolide can be increased when it is combined with Lopinavir.
LovastatinThe metabolism of Flunisolide can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Flunisolide can be increased when it is combined with Luliconazole.
MagaldrateThe bioavailability of Flunisolide can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Flunisolide can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Flunisolide can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Flunisolide can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Flunisolide can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Flunisolide is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flunisolide.
MestranolThe serum concentration of Flunisolide can be increased when it is combined with Mestranol.
MethyclothiazideFlunisolide may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneFlunisolide may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFlunisolide may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Flunisolide can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Minaprine.
MitotaneThe serum concentration of Flunisolide can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Flunisolide.
ModafinilThe serum concentration of Flunisolide can be decreased when it is combined with Modafinil.
NafcillinThe serum concentration of Flunisolide can be decreased when it is combined with Nafcillin.
NefazodoneThe serum concentration of Flunisolide can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Flunisolide can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Neostigmine.
NetupitantThe serum concentration of Flunisolide can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Flunisolide can be decreased when combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Flunisolide is combined with Nicorandil.
NilotinibThe metabolism of Flunisolide can be decreased when combined with Nilotinib.
OlaparibThe metabolism of Flunisolide can be decreased when combined with Olaparib.
OsimertinibThe serum concentration of Flunisolide can be increased when it is combined with Osimertinib.
OxandroloneFlunisolide may increase the fluid retaining activities of Oxandrolone.
OxymetholoneFlunisolide may increase the fluid retaining activities of Oxymetholone.
PalbociclibThe serum concentration of Flunisolide can be increased when it is combined with Palbociclib.
PentobarbitalThe serum concentration of Flunisolide can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Flunisolide can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Flunisolide.
PhenytoinThe serum concentration of Flunisolide can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Physostigmine.
PiretanideFlunisolide may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Flunisolide can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFlunisolide may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Flunisolide can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Flunisolide can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Pyridostigmine.
QuinestrolThe serum concentration of Flunisolide can be increased when it is combined with Quinestrol.
QuinethazoneFlunisolide may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rabies vaccine.
RanolazineThe metabolism of Flunisolide can be decreased when combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Flunisolide.
RifabutinThe serum concentration of Flunisolide can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Flunisolide can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Flunisolide can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Flunisolide can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flunisolide.
SaquinavirThe serum concentration of Flunisolide can be increased when it is combined with Saquinavir.
SildenafilThe metabolism of Flunisolide can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Flunisolide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Flunisolide can be increased when it is combined with Simeprevir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Flunisolide.
St. John's WortThe serum concentration of Flunisolide can be decreased when it is combined with St. John's Wort.
StanozololFlunisolide may increase the fluid retaining activities of Stanozolol.
StiripentolThe serum concentration of Flunisolide can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Flunisolide can be decreased when combined with Sulfisoxazole.
Synthetic Conjugated Estrogens, AThe serum concentration of Flunisolide can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Flunisolide can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Flunisolide.
TelaprevirThe serum concentration of Flunisolide can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Flunisolide can be increased when it is combined with Telithromycin.
TestosteroneFlunisolide may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Flunisolide can be increased when it is combined with Tibolone.
TiclopidineThe metabolism of Flunisolide can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Flunisolide can be decreased when it is combined with Tocilizumab.
TorasemideFlunisolide may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Flunisolide is combined with Trichlorfon.
TrichlormethiazideFlunisolide may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Tubocurarine.
VenlafaxineThe metabolism of Flunisolide can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Flunisolide can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Flunisolide can be increased when it is combined with Voriconazole.
WarfarinFlunisolide may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Flunisolide can be increased when it is combined with Zeranol.
ZiprasidoneThe metabolism of Flunisolide can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Hochhaus G, Moellmann HW: Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents Actions. 1990 Jun;30(3-4):377-80. [PubMed:2386110 ]
  2. Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 2):S434-9. [PubMed:9563368 ]
  3. Valotis A, Hogger P: Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res. 2004 Jul 22;5:7. [PubMed:15285788 ]
  4. Hogger P, Erpenstein U, Rohdewald P, Sorg C: Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res. 1998 Feb;15(2):296-302. [PubMed:9523318 ]
  5. Badia L, Lund V: Topical corticosteroids in nasal polyposis. Drugs. 2001;61(5):573-8. [PubMed:11368283 ]
  6. Philibert D, Bouchoux F, Cerede E, Corallo F, Allaire JM: [Pharmacologic study of the glucocorticoid activity of flunisolide compared with other steroids in the rat]. Allerg Immunol (Paris). 1993 Feb;25(2):77-81. [PubMed:8466638 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:13